CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 222 enrolled
Drug / intervention
Dotarem +1 moredrug
Likely dose
Dotarem 0.2mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01010932
NCT01010932Phase 3Completed
CompareCT.gov

Evaluation of Dotarem-enhanced MRA Compared to Time-Of-Flight (TOF) MRA in the Diagnosis of Carotid and Vertebral Basilar Arterial Disease

Guerbet·interventional·Posted Nov 10, 2009·Updated Jun 16, 2016

In Brief

A Phase 3 clinical trial evaluating Dotarem and TOF MRA for Cerebral Arterial Diseases. Completed, enrolled 222 participants across 1 site.

Detailed Summary

The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCerebral Arterial Diseases
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 10, 2009
Enrollment StartOct 1, 2009
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 16.6 years ago

Interventions

Dotaremdrug

Each subject will receive one injection of Dotarem 0.2ml/kg

TOF MRAother

Each subject will undergo a Time of Flight Magnetic Resonance Angiography (TOF MRA)